💊 Schemes & WelfareMAINS · GS2.13

Jan Aushadhi network crosses 18,646 outlets

India's affordable-generics programme reports a nationwide footprint of 18,646 dedicated medicine stores, on the way to a 25,000-store target by March 2027.

What happened

In a reply tabled in the Lok Sabha, the Department of Pharmaceuticals stated that 18,646 Jan Aushadhi Kendras (JAKs) were operational across the country as on 28 February 2026 under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP).
The reply carried a full State/UT-wise distribution of the stores, signalling that the network has now reached every State and Union Territory rather than clustering in a few States.
Among the figures placed on record: Uttar Pradesh 3,944, Kerala 1,755, Karnataka 1,637, Tamil Nadu 1,559, Bihar 1,127, Madhya Pradesh 634, and 41 in the merged UT of Dadra & Nagar Haveli and Daman & Diu.
The data point is incremental rather than a fresh launch — it is a progress disclosure against the scheme's stated rollout target of 25,000 stores by March 2027.
The wide State coverage and the size of the basket reported alongside (over 2,000 medicines) frame the update as evidence of the scheme reaching scale in its current phase.

Background & context

The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) — literally the "Prime Minister's Indian People's Medicine Scheme" — is the Union government's flagship effort to make quality generic medicines available at affordable prices through dedicated retail outlets branded as Jan Aushadhi Kendras. It is a central-sector programme run by the Department of Pharmaceuticals under the Ministry of Chemicals and Fertilizers, which sets it apart from the centrally-sponsored welfare schemes where States share the cost; here the funding and direction flow from the Centre.

The programme is not a 2015 invention from scratch. Its lineage runs back to the Jan Aushadhi Scheme launched in 2008, which struggled with a thin store network and supply gaps. The scheme was relaunched and re-energised as PMBJP in 2015–16, when its administration was consolidated and the outlet-opening drive was scaled up. Over the following decade the store count climbed from a few hundred to the present figure of over eighteen thousand — the trajectory this Lok Sabha reply documents.

The day-to-day implementing agency is the Pharmaceuticals & Medical Devices Bureau of India (PMBI) — earlier known as the Bureau of Pharma PSUs of India (BPPI). PMBI is the body that procures the generic medicines, manages the warehousing and supply chain to the Kendras, runs the quality-assurance system, and processes the applications of those who wish to open a store. The administering chain therefore reads: Department of Pharmaceuticals (policy and budget) → PMBI (operations and supply) → individual Jan Aushadhi Kendra operators (last-mile retail). The Kendras themselves are opened by entrepreneurs, NGOs, pharmacists, and charitable institutions, who receive a financial incentive on their sales, making the model a public-purpose retail network operated largely through private and not-for-profit partners.

The economic logic the scheme attacks is the wide gap between the cost of a generic molecule and the price of its branded version. Branded medicines in India carry large trade and marketing margins; an unbranded generic with the same active ingredient, the same dosage, and the same regulatory clearance can be sold far cheaper. By procuring such generics in bulk and selling them through a dedicated chain, PMBJP passes that saving to the patient — the reply restates that JAK medicines are roughly 50% to 80% cheaper than their branded equivalents. For a population where a large share of health spending is out-of-pocket and medicines are among the biggest recurring costs, that price wedge is the heart of the scheme's welfare claim.

For Prelims

Full name: Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP); the stores are Jan Aushadhi Kendras (JAKs).
Nodal ministry / department: Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers.
Implementing agency: Pharmaceuticals & Medical Devices Bureau of India (PMBI), formerly BPPI.
Type: Central-sector scheme (Centre-funded and directed), not a centrally-sponsored cost-shared scheme.
Store network: 18,646 JAKs operational as on 28 February 2026; target of 25,000 JAKs by March 2027.
Product basket: 2,110 medicines plus 315 surgical / medical devices and consumables.
Price advantage: JAK medicines about 50%–80% cheaper than branded equivalents.
Quality assurance: supply only from WHO-GMP-certified plants, 100% batch-wise pre-testing before dispatch, and testing in GLP / NABL-accredited laboratories.
Scale of sales: roughly ₹4,728.42 crore (MRP value) of medicines sold over the last three financial years, indicating estimated savings of several thousand crore to consumers.
Leading States by store count (per this reply): Uttar Pradesh 3,944; Kerala 1,755; Karnataka 1,637; Tamil Nadu 1,559; Bihar 1,127.

What it is NOT: PMBJP is not a free-medicine programme — patients buy the generics, only at a far lower price; the welfare benefit is the discount, not free distribution. It is not the same as the AMRIT pharmacy chain (Affordable Medicines and Reliable Implants for Treatment), which sells discounted cancer and cardiovascular drugs and implants from hospital-linked outlets and runs under the Health Ministry's stable rather than the Department of Pharmaceuticals. It is also not a drug price-control mechanism: the capping of medicine prices is done separately by the National Pharmaceutical Pricing Authority (NPPA) using the Drug Prices Control Order, 2013 and the National List of Essential Medicines — PMBJP works on the supply-and-access side, not the price-ceiling side. Finally, the Jan Aushadhi Kendra is a standalone generic-medicine store, distinct from an Ayushman Arogya Mandir (the rebranded health and wellness centre that delivers primary care).

The affordable-healthcare family it sits in (for "how many / match the pairs" questions): PMBJP (affordable generics) · AMRIT pharmacies (discounted cancer, cardiac drugs and implants) · NPPA + DPCO 2013 (price ceilings on scheduled drugs) · the National List of Essential Medicines (the reference list NPPA prices from) · Ayushman Bharat PM-JAY (hospitalisation insurance cover) · PM-ABHIM and Ayushman Arogya Mandirs (health infrastructure and primary care). PMBJP is the generic-medicine retail leg of this set — distinguishing it from the insurance leg (PM-JAY), the price-control leg (NPPA / DPCO), and the infrastructure leg (PM-ABHIM) is exactly the discrimination a Prelims pairing question tests.

For UPSC: PMBJP = central-sector affordable-generics scheme, run by PMBI under the Department of Pharmaceuticals; 18,646 Jan Aushadhi Kendras (Feb 2026), basket of 2,110 medicines + 315 devices, 50–80% cheaper, target 25,000 stores by March 2027. Do not confuse it with AMRIT pharmacies or with NPPA/DPCO price control.

Why it matters

The problem PMBJP addresses is one of the most stubborn features of Indian healthcare: the high share of out-of-pocket health expenditure, of which medicines are typically the single largest line. When a family pays for treatment from its own pocket, the cost of drugs can push it below the poverty line — the so-called catastrophic health expenditure. A retail network that sells the same molecule at half to a fifth of the branded price directly compresses that burden, and does so without the fiscal weight of giving medicines away.

The store-count milestone matters because access is geographic, not just financial. A cheap medicine that is only available in a metro pharmacy does not help a patient in a small town or aspirational district. The State/UT-wise spread reported here — reaching even small merged UTs — is what converts the price advantage into genuine access. It also nudges the wider market: as generic awareness grows through a visible branded chain, it can shift prescribing behaviour and dilute the stigma that "branded equals better", which is the cultural barrier generics have always faced in India.

At the same time the scheme carries honest limits worth naming. Its reach still depends on doctors prescribing by generic name and on patients trusting an unbranded product; the quality-assurance architecture (WHO-GMP sourcing, 100% batch testing, NABL labs) exists precisely to answer that trust question. Sustaining store viability also depends on the incentive structure for operators and on uninterrupted supply from PMBI's warehouses. The 25,000-store target is therefore as much about supply-chain depth and operator economics as about cutting ribbons.

For Mains

Exemplification

PMBJP is a ready example of a low-fiscal-cost, high-reach welfare intervention — it reduces out-of-pocket medicine spending through a procurement-and-retail model rather than a subsidy, making it a clean illustration of "smart" welfare design in any GS2.13 health answer.

Substantiation

The hard numbers — 18,646 stores reaching 25,000 by March 2027, a 2,110-medicine basket, 50–80% price reduction, and ₹4,728.42 crore of sales over three years — supply the quantitative spine for arguments on affordable healthcare and the reduction of catastrophic health expenditure.

Way-forward

The scheme points the way for deepening access: expanding the basket, strengthening generic prescribing norms, and tightening supply chains to underserved districts — usable as a concrete recommendation in answers on universal health coverage.

Problematisation

It also surfaces the gap it must still close — physician and patient hesitancy toward generics, and store viability in thinly-populated areas — letting you write a balanced answer rather than a one-sided endorsement.

Deploys into: health and human-resource development; welfare interventions that lower out-of-pocket expenditure; affordable-medicine and universal-health-coverage debates; governance models that deliver public goods through private and not-for-profit partners. (GS2.13; also referable in GS2.10 on government policies and GS3.5/economy of subsidies-vs-access.)

Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers · 2026-03-13 · PRID 2239566 · PIB source ↗